IN2012DN02046A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02046A
IN2012DN02046A IN2046DEN2012A IN2012DN02046A IN 2012DN02046 A IN2012DN02046 A IN 2012DN02046A IN 2046DEN2012 A IN2046DEN2012 A IN 2046DEN2012A IN 2012DN02046 A IN2012DN02046 A IN 2012DN02046A
Authority
IN
India
Prior art keywords
tvemps
compositions
mammal
methods
present specification
Prior art date
Application number
Inventor
P S Jacky Birgitte
E Garay Patton
Molina Yanira
G Stathakis Dean
Francis Joseph
Roger Aoki Kei
Fernandez-Salas Ester
E Steward Lance
Ghanshani Sanjiv
J Hunt Terrence
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2012DN02046A publication Critical patent/IN2012DN02046A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
IN2046DEN2012 2009-08-14 2010-08-16 IN2012DN02046A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23394709P 2009-08-14 2009-08-14
PCT/US2010/045659 WO2011020115A2 (en) 2009-08-14 2010-08-16 Methods of treating cancer using growth factor retargeted endopeptidases

Publications (1)

Publication Number Publication Date
IN2012DN02046A true IN2012DN02046A (en) 2015-08-21

Family

ID=43478303

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2046DEN2012 IN2012DN02046A (en) 2009-08-14 2010-08-16

Country Status (9)

Country Link
US (2) US20110070186A1 (en)
EP (1) EP2464366A2 (en)
KR (1) KR20140015129A (en)
CN (1) CN102971001A (en)
AU (1) AU2010282274A1 (en)
CA (1) CA2771181A1 (en)
IL (1) IL218066A0 (en)
IN (1) IN2012DN02046A (en)
WO (1) WO2011020115A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
WO2013033680A1 (en) 2011-09-02 2013-03-07 Lifenet Health Bmp peptides & methods of use
US11078248B2 (en) 2010-03-19 2021-08-03 Lifenet Health BMP peptides and methods of use
EP2627350A1 (en) 2010-10-14 2013-08-21 Allergan, Inc. Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
WO2012112422A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
WO2012150254A1 (en) * 2011-05-02 2012-11-08 Baxter International Inc. Fgf based fibrin binding peptides
US9764009B2 (en) 2011-06-13 2017-09-19 Allergan, Inc. Treatment of psychological trauma
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
WO2014100019A1 (en) 2012-12-18 2014-06-26 Allergan, Inc. Prophylactic treatment of herpes recurrence
CN104634982B (en) * 2013-11-06 2016-08-17 中国科学院上海生命科学研究院 VEGF-C purposes in preparation septicemia and serious bacterial infections diagnostic reagent
EP3194974B1 (en) * 2014-09-16 2019-10-23 Regeneron Pharmaceuticals, Inc. Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
CA3015392A1 (en) 2015-03-03 2016-09-09 Wilfred Jefferies Modulation of cancer immunity with type 2 innate lymphoid cells, interleukin 33, and/or interferon induced protein 44
CN108070651A (en) * 2016-11-07 2018-05-25 苏州安康盟医疗科技有限公司 A kind of diagnostic analysis/prognostic analysis method for assessing CRC risks of recurrence
KR102277147B1 (en) * 2017-12-13 2021-07-13 건국대학교 산학협력단 Use of peptides derived from fibroblast growth factor to promote osteogenic or chondrogenic differentiation
WO2018141313A2 (en) * 2018-04-17 2018-08-09 Novo Nordisk A/S Uses of fgf-4 compounds
GB201900621D0 (en) * 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
CN114075272B (en) * 2020-08-10 2023-09-22 杭州俊丰生物工程有限公司 Preparation method of human neuregulin 4
CN118146395A (en) * 2021-02-08 2024-06-07 浙江大学 Chimeric antigen receptor using endogenous protein molecules to replace single domain antibodies
CN113621690B (en) * 2021-07-26 2023-08-22 山西医科大学 Application of interleukin 32 as target in screening and targeting medicine for treating esophageal squamous carcinoma
CN114295839B (en) * 2021-08-11 2024-06-07 首都医科大学附属北京地坛医院 Application of HOXB7 protein in preparation of kit for identifying oligodendroglioma and astrocytoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2006059093A2 (en) 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
EP1877073B1 (en) 2004-12-01 2013-09-25 The Secretary of State for Health Non-cytotoxic protein conjugates
EP2316847A3 (en) * 2005-03-15 2012-01-18 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US7993656B2 (en) * 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells

Also Published As

Publication number Publication date
EP2464366A2 (en) 2012-06-20
KR20140015129A (en) 2014-02-06
US20130195838A1 (en) 2013-08-01
IL218066A0 (en) 2012-04-30
US20110070186A1 (en) 2011-03-24
WO2011020115A2 (en) 2011-02-17
CN102971001A (en) 2013-03-13
CA2771181A1 (en) 2011-02-17
AU2010282274A1 (en) 2012-03-15
WO2011020115A3 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
IN2012DN02046A (en)
WO2011020056A3 (en) Methods of treating cancer using galanin retargeted endpeptidases
WO2011020114A3 (en) Methods of treating cancer using tachykinin retargeted endopeptidases
WO2011020119A3 (en) Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
WO2011020117A3 (en) Methods of treating cancer using neurotrophin retargeted endopeptidases
HK1216880A1 (en) Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.
MX344786B (en) Compositions and methods for treating gaucher disease.
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
HRP20160949T1 (en) Novel compositions and methods for cancer treatment
IL218987A0 (en) Methods and compositions for treating cancer
MX2010008817A (en) Treatment of metastatic stage prostate cancer with degarelix.
ZA201203603B (en) Lyophilization methods, compositions, and kits
PL2340042T3 (en) Methods and compositions for the treatment of cancer
EP2419136A4 (en) Compositions and methods for treating cancer
SG10201500124VA (en) Methods and Compositions for Treating Cancer
EP2340027A4 (en) Methods and compositions for the treatment of cancer
EP2381920A4 (en) Methods and compositions for treating p.acnes
MY161601A (en) Films and compositions comprising the same
IL219636A0 (en) Methods and compositions for treating solid tumors and other malignancies
WO2011057220A9 (en) Compositions and methods for treating lymphoma
EP2137213A4 (en) Methods and compositions for treating prostate cancer
EP2597949A4 (en) Sub-micron compositions
IL214757A0 (en) Compositions and methods to prevent and/or treat cancer with pa-card
AU2010298020A8 (en) Combination
SG178967A1 (en) Antimicrobial compositions and products